Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: Comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T

Abstract

Consistently greater tumor enhancement was noted at all measured timepoints following contrast injection with gadobutrol compared to both gadopentetate dimeglumine and gadoterate meglumine at 1.5 T. A substantial further improvement in tumor enhancement was noted using gadobutrol at 3 T.